We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Resistant Cancer Cells Flush Out Drugs

By Biotechdaily staff writers
Posted on 19 Dec 2005
Researchers have identified a mechanism that allows cancer cells to flush out chemotherapeutic drugs before they reach a concentration great enough to kill the cells.

Investigators at the Technion-Israel Institute of Technology (Haifa; Israel) were continuing studies on a mutated form of the ABCG2 transporter protein. More...
Previous work had shown that cells possessing this form of the protein were resistant to chemotherapy.

In the current study, published in the December 1, 2005, issue of Cancer Research, they used high-resolution electron microscopy to reveal that a line of MCF-7 breast cancer cells developed balloon-like extracellular vesicles that sequestered the anticancer drug mitoxantrone. The membrane of these extracellular vesicles contained microvilli-like invaginations protruding into the intravesicular lumen. The invaginations served to increase the surface area of the membrane and increase its efficiency in transporting the drug. After 12 hours of incubation with mitoxantrone, the estimated intravesicular drug concentration was nearly 1,000-fold higher than in the culture medium.

Senior author Dr. Yehuda Assaraf, professor of biology at the Technion, explained, "The mutated ABCG2 protein is found in large quantities in the extracellular membrane of these vesicles located among the neighboring cancer cells. It ‘cleans' the cancer cells of chemotherapy drugs such as mitoxantrone and collects them in these vesicles, which enlarge and inflate until the drug concentration is a thousand times greater than in the surrounding cell culture. This is a completely new resistance mechanism practiced by breast cancer cells to fight the lethal activities of anticancer drugs.”







Related Links:
Technion-Israel Institute of Technology

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
New
Portable POCT Blood Gas Analyzer
BD100
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Blood Test Measuring Tumor Proliferation May Guide Treatment Sequencing in Metastatic Melanoma

Metastatic melanoma remains difficult to manage because outcomes vary widely and early prognostic markers are limited. About half of patients carry a BRAF gene mutation, giving clinicians several first-line... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers

Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.